Skip to main content
. 2019 Feb 15;11:159–168. doi: 10.2147/CEOR.S192235

Figure 2.

Figure 2

Probability of cost-effectiveness of AS treatments at different willingness-to-pay thresholds for biologic-naïve patients.

Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; SEC, secukinumab.